

Our Patient Access Philosophy & Progress

At Alnylam, we believe that discovery and development is only the first step in delivering the promise of RNAi therapeutics to as many patients as possible.

Our **Patient Access Philosophy** guides our role in access, affordability, and outcomes as they relate to the value our therapies bring to the patient communities and therapeutic areas we serve.

Every year, we measure and report our progress in three areas - value and impact, achieving better outcomes, and being proactive and accountable. The following is data as of year-end 2023.

Sustainable Value and Significant Impact

We believe it is our responsibility to push the boundaries of scientific discovery, clinical development, and delivery to fuel significant, sustainable patient impact.

5,100+

patients on our commercial therapies worldwide

830+

patients worldwide who received access to our therapies through compassionate use to date

60+

countries where patients can access our therapies by way of direct or distributor infrastructure

40+

countries where patients have received access to our therapies

2,400+

patients participating in clinical trials for our therapies

15+

patient voice inclusion interviews

Connecting to Achieve Better Outcomes

We believe that together with partners in the healthcare ecosystem, we can reduce barriers to our medicines to improve outcomes for all stakeholders in the patient journey – most importantly, for the patients who may benefit from them.

> 97%

of U.S. residents with confirmed access to our therapies across commercial, Medicare, Medicaid, and other government payer categories

1,600+

U.S. patients enrolled in Alnylam Assist®

ZERO

U.S. cost-share

- AMVUTTRA® & ONPATTRO® : > 65%
- GIVLAARI® : 80%
- OXLUMO® : 95%

80%

of EU countries have access to at least one of our therapies

4.9

average U.S. Alnylam Assist® patient satisfaction score for all of our therapies on a 5.0 scale

35%

of U.S. patients receiving any financial assistance or participating in access programs across all our therapies

38 days

average time to access in Europe for all of our therapies

55+

value-based agreements signed with U.S. payers across therapies

(by way of listing in German price database, Lauer-Taxe)

CONTINUED ON BACK PAGE

Proactive and Accountable

We believe that biopharmaceutical companies play a critical role in the patient's journey to accessing innovative therapeutic options and should be accountable for progress.

40+

patient-reported outcome measures in clinical trials

100,000+

samples genotyped through Alnylam Act® or GeneAct™ since the program began

90+

patient advocacy organizations engaged in Alnylam's network globally

100+

medical societies engaged

1,180+

patients participating in registries

100+

patient advocacy events supported worldwide

Definitions of Key Alnylam Programs Related to Access and Affordability

Expanding Patient Access Programs

Through various programs, we provide patients with access to diagnostic resources and genetic testing, and we remove barriers for patients to gain access to our commercially available therapies. In addition, we enable access to our investigational drugs for treatment outside clinical trials when no comparable or satisfactory alternative therapy options are available. Our key programs include:

- **Alnylam Act®** offers eligible patients in the U.S., Canada, and Brazil no-charge, third-party genetic testing and counseling.*
- **GeneAct™** offers third-party genetic testing in selected countries across Europe and Middle East.*
- **Alnylam Assist®** helps patients who are prescribed our medicines in the U.S. and Canada understand insurance coverage, know their options for financial support, and access educational materials and resources.
- **Alnylam's Compassionate Use Policy** outlines the circumstances in which we will consider providing treatment for an individual patient outside a clinical trial. We evaluate all requests in a fair and equitable manner.

Statistics reflect Alnylam Data on File

* Healthcare professionals or patients who use these programs have no obligation to recommend, purchase, order, prescribe, promote, administer, use, or support any Alnylam product

For more information on Alnylam's approach to access and affordability, please visit alnylam.com/access